A pleasure, as always, to work with @LuskinMarlise@DanaFarber to review and interpret data for #tagraxofusp study/approval/clinical use including toxicity prevention and management (esp. #CLS) and pose some of open questions for its use in BPDCN https://t.co/a07NieHc6G
Our latest manuscript State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes, great summary by @Volpe_MD and collaborating with @garciamanero https://t.co/JrzD5OiOXp @MoffittNews@MoffittHemOnc
Excited to share This unique experience - 2023 AML updates review. Honored to be mentored by a true giant @Dr.Richard.Stone and collaborate with @MaxStahlMD. We summarized recent advances in AML and presented our approach to patient care. @AjHematology
https://t.co/VPXmr0LB14
Clonal Cytopenia of Unknown Significance: To Treat or Not To Treat? | ASH Clinical News | American Society of Hematology https://t.co/HGFGMVdkMs Always a privilege to debate @DavidSteensma@ASH_hematology#CCUS#CHIP@MayoClinicCIM
After 4 reviews, many tears, and the fear of sharing my story.
"My White Coat Doesn't Fit" was just published as an @JCO_ASCO Art of Oncology Article.
Article here: https://t.co/L34P0dpRpt
SF3B1 mutation in the context of therapy‐related myelodysplastic syndromes https://t.co/Bda3DGJ4K3 Our latest manuscript, we should reconsider defining t-MDS based on molecular profile. Kudos to @Volpe_MD@MoffittNews@MoffittResearch@MoffittHemOnc
Incorporating gene mutations with standard parameters for #MDS stratification in an algorithm for routine practice. That is the #IPSSM, an international study from the #IWG, led by @PapaemmanuilLab, supported by @MDSFoundation, and today in @NEJMEvidence https://t.co/A3YqxqkKHz